This statistic depicts the total expenditure on health as a share of GDP (gross domestic product) in selected European countries in 2022. In that year, Switzerland spent the largest share of GDP on healthcare at ** percent, followed by Germany at **** percent.

In 2023, the total healthcare expenditure per capita was approximately ******* U.S. dollars. Followed by Norway, which spent ******* U.S. dollars per capita.

The current healthcare spending in Europe was forecast to continuously increase between 2024 and 2029 by in total 843.8 billion U.S. dollars (+28.57 percent). After the seventh consecutive increasing year, the spending is estimated to reach 3.8 trillion U.S. dollars and therefore a new peak in 2029. According to Worldbank health spending includes expenditures with regards to healthcare services and goods. The spending refers to current spending of both governments and consumers.The shown data are an excerpt of Statista's Key Market Indicators (KMI). The KMI are a collection of primary and secondary indicators on the macro-economic, demographic and technological environment in up to 150 countries and regions worldwide. All indicators are sourced from international and national statistical offices, trade associations and the trade press and they are processed to generate comparable data sets (see supplementary notes under details for more information).Find more key insights for the current healthcare spending in countries like Worldwide and Caribbean.

This table describes which different types of revenues the healthcare expenditure financing schemes have. In this table, the health care expenditure in current prices is broken down by type of financing (such as the Health Insurance Act) into the various types of revenue, such as the income-related health insurance contribution. The classifications used are those of the System of Health Accounts of Eurostat, Organization for Economic Co-operation and Development (OECD) and the World Health Organization (WHO; World Health Organization). Data available from: 1998 Status of the figures: The figures for 2020 and 2021 included in the table are more provisional. Figures for previous years are final. The total expenses according to the financing arrangements are equal to the total healthcare expenses as determined in the Healthcare Accounts. Changes as of 21 July 2023: The more detailed provisional figures for 2020 and 2021 and the final figures for 2019 have been published. When will new numbers come out? - The provisional figures for 2022 will be published in the first quarter of 2024. - The final figures for 2020 and the adjusted figures for 2021 and 2022 will be published in the second quarter of 2024.

In 2022, of the total healthcare expenditure of the 27 European Union countries, approximately ** percent went to inpatient curative and rehabilitative care, while ***** percent was spent on long-term care. Another ***** percent was spent on pharmaceuticals and other medical non-durable goods.

Contribution of the 10 NCDs as % of total healthcare spending, by region and scenario (over 2014–2050).

This table contains information on expenditure and financing in current prices on the health care used by residents in the Netherlands in one year. All activities within the area of health care are included, irrespective of whether they are performed within or outside the health care sector. These figures are based on the definition of the System of Health Accounts as used by EUROSTAT, the OECD and the WHO. The figures are derived from the Dutch Health and Social Care Accounts, which cover a broader range of activities (including e.g. child day care, welfare, and social services). The Dutch Health and Social Care Accounts include exports. In this table it can be found in the function M1(HC)+ : Other goods, services + exports. This table also shows how the total figure in accordance with the System of Health Accounts is calculated from the total figure of the Dutch Health and Social Care Accounts(with figures on 2007 as example): Total figure of the Dutch Health and Social Care Accounts (74643 million euro) -/- health-related activities (7687 million euro) -/- other goods, services and exports (including welfare and children’s day care) (9990 million euro) = Total current expenditure on health (56966 million euro) +/+ capital expenditure by health care providers (investments) (4581 million euro) = Total expenditure on health (61547 million euro) Data available from 2005 till 2013 Status of the figures: The figures for 2012 and 2013 are revised provisional. Because this table is discontinued, figures will not be updated anymore. The figures for the years 2005 till 2011 are final. Changes as of 21 May 2015: This table has been discontinued. When will new figures be published? Not applicable

In 2023, around *** percent of healthcare expenditure in Europe went on medical technology. Within this share, medical devices (including imaging) accounted for *** percent and in vitro diagnostics accounted for *** percent.

European Healthcare Expenditure on Residential Long-Term Care Facilities by Country, 2023 Discover more data with ReportLinker!

Evolution of total annual predicted costs (bn Euros) by region, year and scenario.

Quantifies the economic resources dedicated to health functions, excluding capital investment. Concerns primarily healthcare goods and services consumed by residents, irrespective of where that consumption takes place or who is paying for it. Data are collected according to SHA2011 methodology.

Multivariable linear regression analysis for the total costs per patient.

This table shows the expenditure on health care used by residents of the Netherlands in one year. Healthcare is defined according to the international definition of the System of Health Accounts. The figures are comparable internationally with Eurostat, OECD and WHO publications. All healthcare activities count, regardless of whether they take place inside or outside the healthcare sector. The figures are derived from the Care Accounts, which includes more activities, such as youth care, welfare work, social services and childcare. The table also shows how from the total figure according to the Health Care Accounts to the international total figure (with figures from 2007 as an example):

Total expenditure according to the Health Care Accounts (74,643 million euro) —/- health related expenditure, such as household care within elderly care (EUR 7,687 million)

—/- expenditure on non-health care according to the international definition, such as childcare, including export (foreign financing of expenditure by Dutch healthcare providers for non-residents) (9.990 million euro)

= Total current expenditure on health care (EUR 56.966 million)

+/+ investments by healthcare providers (4.581 million euro)

= Total health expenditure according to the international definition (EUR 61,547 million)

Data available from 2005 to 2013

Status of the figures:

The figures for 2012 and 2013 are further provisional. As this table has been discontinued, these figures are no longer definitive. Figures for 2005 to 2011 are final.

Changes as of 21 May 2015:

This table has been discontinued.

When are new figures coming?

No longer applicable.

The European healthcare big data analytics market is experiencing robust growth, driven by the increasing volume of healthcare data generated through electronic health records (EHRs), wearable devices, and other digital health technologies. This surge in data necessitates advanced analytics capabilities to improve patient care, optimize operational efficiency, and accelerate drug discovery. The market's Compound Annual Growth Rate (CAGR) of 19% from 2019 to 2024 signifies significant market expansion, projected to continue into the forecast period (2025-2033). Key drivers include the rising prevalence of chronic diseases demanding personalized medicine, stringent regulatory requirements for data security and interoperability, and government initiatives promoting digital health transformation across Europe. The market is segmented by technology type (predictive, prescriptive, and descriptive analytics), application (clinical, financial, and operational), product (hardware, software, and services), delivery mode (on-premise and cloud-based), and end-user (healthcare providers, pharmaceutical and biotechnology companies, and academic organizations). The strong presence of major players like IBM, Oracle, Cerner, and McKesson indicates a competitive yet rapidly evolving landscape. Growth is particularly strong in countries like the UK, Germany, and France, reflecting higher healthcare expenditure and technological adoption rates. However, challenges remain, including data privacy concerns, the need for robust cybersecurity infrastructure, and the integration of legacy systems with new data analytics platforms. Overcoming these hurdles is key to unlocking the full potential of big data analytics in improving healthcare outcomes across Europe. The projected market value for 2025 serves as a strong baseline for forecasting future growth. Considering the 19% CAGR and the inherent growth potential in the healthcare sector, a sustained, albeit slightly moderated, growth rate is anticipated for the coming years. The market is expected to see continued investment in cloud-based solutions, driven by their scalability, cost-effectiveness, and accessibility. The focus on predictive analytics will likely increase, aiming to anticipate patient needs and optimize resource allocation. Furthermore, the integration of artificial intelligence (AI) and machine learning (ML) within big data analytics platforms is poised to accelerate innovation and further propel market growth. The ongoing emphasis on interoperability across healthcare systems will stimulate demand for integrated data analytics solutions, leading to greater efficiency and improved data-driven decision making. This continued growth will solidify Europe's position as a key player in the global healthcare big data analytics market. Recent developments include: May 2022 : The European Health Data Space was introduced by the European Commission (EHDS). The EHDS should assist the EU in significantly improving how healthcare is supplied to people throughout Europe. People should be able to manage and use their health information in their nation or another Member State. It should promote a single market for services and goods related to digital health. Additionally, it should guarantee complete adherence to the stringent data protection requirements set by the EU and provide a consistent, reliable, and effective framework for using health data for research, innovation, policy-making, and regulatory activities., November 2022 : The largest health services provider in Israel, Clalit, and IQVIA, a leading global provider of advanced analytics, technological solutions, and clinical research services to the life sciences sector, have announced a long-term partnership. The partnership assures IQVIA it can meet the pharmaceutical industry's interest in Israel as a top location for research and innovation by combining Clalit's aim to improve policy and healthcare with IQVIA's Connected Intelligence.. Key drivers for this market are: Reduced Cost of Care and Prediction of Possible Emergency Services, Increasing Evidence-based Activities and Shift from Volume- to Value-based Commissioning. Potential restraints include: Reduced Cost of Care and Prediction of Possible Emergency Services, Increasing Evidence-based Activities and Shift from Volume- to Value-based Commissioning. Notable trends are: Clinical Data Analytics to Witness Significant Growth Over the Forecast Period.

The current healthcare spending per capita in Russia was forecast to continuously increase between 2024 and 2029 by in total ***** U.S. dollars (+***** percent). After the sixth consecutive increasing year, the spending is estimated to reach ******* U.S. dollars and therefore a new peak in 2029. Depicted here is the average per capita spending, in a given country or region, with regards to healthcare. The spending refers to the average current spending of both governments and consumers per inhabitant.The shown data are an excerpt of Statista's Key Market Indicators (KMI). The KMI are a collection of primary and secondary indicators on the macro-economic, demographic and technological environment in up to *** countries and regions worldwide. All indicators are sourced from international and national statistical offices, trade associations and the trade press and they are processed to generate comparable data sets (see supplementary notes under details for more information).Find more key insights for the current healthcare spending per capita in countries like Central & Western Europe and Eastern Europe.

The European healthcare big data analytics market is experiencing robust growth, driven by the increasing volume of patient data generated from electronic health records (EHRs), wearables, and other connected health devices. A compound annual growth rate (CAGR) of 19% from 2019 to 2024 suggests a significant market expansion, and this momentum is projected to continue through 2033. Key drivers include the rising prevalence of chronic diseases necessitating improved disease management, the increasing demand for personalized medicine, and government initiatives promoting the adoption of digital health technologies across Europe. The market is segmented by technology type (predictive, prescriptive, and descriptive analytics), application (clinical, financial, and operational data analytics), product (hardware, software, and services), mode of delivery (on-premise and cloud-based), and end-user (healthcare providers, pharmaceutical companies, biotechnology firms, and academic organizations). The strong presence of major players like SAS Institute, IBM, and McKesson underscores the market's maturity and competitive landscape. Specific regional growth within Europe will likely be influenced by factors such as national healthcare policies, digital infrastructure development, and data privacy regulations, with countries like the United Kingdom, Germany, and France expected to lead the market due to their advanced healthcare systems and substantial investments in digital health initiatives. The cloud-based model is expected to dominate the market due to its scalability, cost-effectiveness, and accessibility. Predictive analytics, enabling proactive interventions and risk stratification, is gaining significant traction, particularly within the clinical data analytics segment. However, challenges such as data interoperability issues, concerns around data security and privacy (GDPR compliance being particularly relevant in Europe), and the high cost of implementation could potentially restrain market growth. Nevertheless, the overall outlook for the European healthcare big data analytics market remains positive, promising substantial opportunities for technology providers and healthcare organizations alike to improve patient care, optimize operational efficiency, and drive innovation in healthcare delivery. The market’s size in 2025 is estimated at €X billion (a figure readily obtainable through market research databases given the specified CAGR and available historical data), providing a strong base for future growth projections. This report provides a detailed analysis of the burgeoning Europe healthcare big data analytics market, projecting its growth from 2019 to 2033. With a base year of 2025 and an estimated market value of XXX million, this study offers invaluable insights for stakeholders across the healthcare ecosystem. We delve into market segmentation, competitive landscape, and key trends shaping this dynamic sector, empowering businesses to make informed strategic decisions. The report covers the period from 2019 to 2024 (historical period), with a forecast period spanning 2025 to 2033. Recent developments include: May 2022 : The European Health Data Space was introduced by the European Commission (EHDS). The EHDS should assist the EU in significantly improving how healthcare is supplied to people throughout Europe. People should be able to manage and use their health information in their nation or another Member State. It should promote a single market for services and goods related to digital health. Additionally, it should guarantee complete adherence to the stringent data protection requirements set by the EU and provide a consistent, reliable, and effective framework for using health data for research, innovation, policy-making, and regulatory activities., November 2022 : The largest health services provider in Israel, Clalit, and IQVIA, a leading global provider of advanced analytics, technological solutions, and clinical research services to the life sciences sector, have announced a long-term partnership. The partnership assures IQVIA it can meet the pharmaceutical industry's interest in Israel as a top location for research and innovation by combining Clalit's aim to improve policy and healthcare with IQVIA's Connected Intelligence.. Key drivers for this market are: Reduced Cost of Care and Prediction of Possible Emergency Services, Increasing Evidence-based Activities and Shift from Volume- to Value-based Commissioning. Potential restraints include: Maintaining the Privacy and Integrity of Patient Data. Notable trends are: Clinical Data Analytics to Witness Significant Growth Over the Forecast Period.

In 2023, the United States had the highest per capita health expenditure among OECD countries. At that time, per capita health expenditure in the U.S. amounted over ****** U.S. dollars, significantly higher than in Switzerland, the country with the second-highest per capita health expenditure. Norway, Germany and Austria are also within the top five countries with the highest per capita health expenditure. The United States also spent the highest share of it’s gross domestic product on health care, with **** percent of its GDP spent on health care services. Health Expenditure in the U.S. The United States is the highest spending country worldwide when it comes to health care. In 2022, total health expenditure in the U.S. exceeded **** trillion dollars. Expenditure as a percentage of GDP is projected to increase to approximately ** percent by the year 2031. Distribution of Health Expenditure in the U.S. Health expenditure in the United States is spread out across multiple categories such as nursing home facilities, home health care, and prescription drugs. As of 2022, the majority of health expenditure in the United States was spent on hospital care, accounting for a bit less than *** third of all health spending. Hospital care was followed by spending on physician and clinical services which accounted for ** percent of overall health expenditure.

Total hospital costs per cancer type.

The Population Health Management (PHM) solutions market is experiencing robust growth, driven by increasing prevalence of chronic diseases, aging populations, and the rising demand for cost-effective healthcare delivery. The market, valued at approximately $35 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2033. This significant expansion is fueled by several key factors. Technological advancements, such as artificial intelligence (AI) and machine learning (ML), are enhancing predictive analytics and personalized interventions, leading to improved patient outcomes and reduced healthcare costs. Furthermore, government initiatives promoting value-based care and interoperability are creating a favorable regulatory environment for PHM solutions. The increasing adoption of cloud-based solutions and the growing penetration of wearable technology are further bolstering market growth. The segment encompassing software solutions holds a significant market share due to its ability to streamline workflows and improve data analysis. Hospitals currently dominate the application segment, though home care and elderly nursing homes are witnessing substantial growth as healthcare shifts towards patient-centric models. Key players like Cerner, McKesson, Allscripts, and Epic Systems are investing heavily in research and development to strengthen their market positions through innovation and strategic acquisitions. The geographical landscape demonstrates strong growth across North America and Europe, driven by advanced healthcare infrastructure and high adoption rates. However, emerging economies in Asia-Pacific and the Middle East & Africa are showing promising potential for future growth, fueled by rising healthcare spending and government investments in digital health initiatives. Restraints to market growth include data security and privacy concerns, the high cost of implementation and maintenance of PHM systems, and the need for robust interoperability standards across different healthcare systems. Despite these challenges, the overall market outlook for PHM solutions remains positive, with substantial opportunities for growth and innovation in the coming years. The market is expected to reach approximately $110 billion by 2033. This forecast is derived from an estimated 2025 market size and projected CAGR, considering the aforementioned market drivers and restraints.

Background: Sternal wound infections (SWIs) can be some of the most complex surgical-site infections (SSIs) and pose a considerable risk following coronary artery bypass graft surgery (CABG).Objective: To capture the cost burden of SWIs following CABG across European countries.Methods: We modeled a standardized care pathway for CABG, starting at the point of surgery and extending to 1-year post surgery. The Markov model captures the incidence and cost of an SWI (deep or superficial SWIs). The cost burden is calculated from a hospital perspective such that the main inputs relating to costs were intensive-care-unit (ICU) and general-ward (GW) days. Outpatient care, not in the hospital setting, has no cost in this analysis. Model input parameters were taken from Eurostat and a review of published, peer-reviewed literature. European countries were included in this analysis when values for 50% of the required input parameters per country were identified. Missing data points were interpolated from available data. The robustness of results was assessed via probabilistic sensitivity analysis.Results: Full required input data were available for 8 European countries; a further 18 countries had sufficient data for analysis. The median (interquartile range) for SWI incidence across the 26 countries was 3.9% (2.9–5.6%). The total burden for all 26 countries of SWIs after CABG was €170.8 million. These costs were made up of 25,751 additional ICU days, 137,588 additional GW days, and 7,704 readmissions. The mean cost of an SWI ranged from €8,924 in Poland to €21,321 in Denmark. Relative to the costs of post-CABG care without an SWI complication, the incremental cost of an SWI was highest in Greece (24.9% increase) and lowest in the UK (3.8% increase) with a median (interquartile range) of 12% (10–16%) across all 26 countries.Conclusions: SWIs following CABG present a considerable burden to healthcare budgets.